FCGR2A and myeloid sarcoma: Given the clinical efficacy and increasing use of lymphocyte‐depleting antibodies in the therapeutic landscape of MS and other neurological diseases, our initial assessment provides incentive to conduct larger prospective studies in order to evaluate the impact of FcγR polymorphisms on clinical outcomes and in vivo mechanisms of therapeutic antibodies in MS.